Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2020

View Archived Issues

Microbiome metabolites as immunotherapy adjuvants

Oxygen therapy harms lungs via lung, gut microbiome

Positive preclinical data presented for multi-target COVID-19 vaccine

T-2143, a novel HSP90-PI3K drug conjugate with promising activity in cancer models

Discovery of a novel FASN inhibitor with promising activity in model of AD

BrightGene Bio-Medical Technology identifies Gly12Cys mutant GTPase KRAS inhibitors

New PD-1/PD-L1 and/or PD-L1/CD80 interaction inhibitors patented by Betta Pharmaceuticals

Jiangsu Vcare Pharmatech discovers JAK inhibitors

Zhejiang Hisun Pharmaceutical presents new RET inhibitors

University of Queensland, Preveceutical Medical patent delta- and kappa-opioid receptor antagonists

Update on development of PGX-YBG inhalable therapeutic for COVID-19

First patient dosed in phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma

Topline data presented from phase II study of elobixibat in NAFLD and NASH

FDA issues complete response letter for filgotinib for the treatment of RA

Promising interim data presented from phase II study of ERC-1671 in recurrent GBM

Phase II study of QBECO SSI in colorectal cancer approved in Israel

Evotec and Novo Nordisk collaborate to develop novel therapies for CKD

Targeting the adenosine A2A receptor may prevent osteoarthritis progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...